Harnessing the anticancer activity of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, using rational combination strategies for breast cancer and other malignancies

被引：0
|
作者：
Annis, A. [1 ]
Ren, J. G. [1 ]
Carvajal, L. A. [1 ]
Santiago, S. [1 ]
Narasimhan, N. [1 ]
Sutton, D. [1 ]
Pairawan, S. S. [2 ]
Guerlavais, V. [1 ]
Meric-Bernstam, F. [2 ]
Aivado, M. [1 ]
机构：
[1] Aileron Therapeut Inc, Cambridge, MA USA
[2] MD Anderson, Invest Canc Therapeut, Houston, TX USA
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
443 (PB-10
引用
收藏
页码：E143 / E144
页数：2
相关论文
共 29 条
  • [1] The investigational peptide drug ALRN-6924, a dual inhibitor of MDMX and MDM2, is an effective myelopreservation agent
    Carvajal, Luis A.
    Sutton, David
    Mounir, Mariam
    McClanaghan, Joseph
    Guerlavais, Vincent
    Aivado, Manuel
    Vukovic, Vojislav
    Annis, Allen
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [2] The investigational chemoprotection drug ALRN-6924, a dual inhibitor of MDMX and MDM2, shows potential for radioprotection
    Annis, Allen
    Sutton, David
    Aivado, Manuel
    Vukovic, Vojislav
    [J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [3] The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, and the CDK4/6 inhibitors palbociclib or abemaciclib synergistically enhance each other's in vitro and in vivo anticancer activity
    Annis, A.
    Carvajal, L. A.
    Ren, J-G
    Sutton, D.
    Santiago, S.
    Narasimhan, N.
    Guerlavais, V.
    Aivado, M.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [4] ALRN-6924 IS A DUAL MDMX/MDM2 INHIBITOR AND CAN PROTECT THE BONE MARROW OF CANCER PATIENTS TREATED WITH CHEMOTHERAPY
    Vukovic, Vojislav
    Annis, Allen
    Ferrari, Dora
    Aivado, Manuel
    [J]. EXPERIMENTAL HEMATOLOGY, 2021, 100 : S61 - S61
  • [5] Pseudoprogression (PsP) in Patients with Peripheral T-Cell Lymphoma (PTCL) Treated with the Novel Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2
    Shustov, Andrei R.
    Mehta, Amitkumar
    Sokol, Lubomir
    Carvajal, Luis A.
    Guerlavais, Vincent
    Samant, Manoj
    Narasimhan, Narayana
    Sutton, David
    Annis, D. Allen
    Pinchasik, Dawn
    Aivado, Manuel
    Korn, Ronald
    [J]. BLOOD, 2018, 132
  • [6] Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924
    Andric, Z.
    Ceric, T.
    Stanetic, M.
    Rancic, M.
    Jakopovic, M.
    Aix, S. Ponce
    Ramlau, R.
    Smit, E.
    Ulanska, M.
    Caldwell, C.
    Ferrari, D.
    Annis, A.
    Vukovic, V.
    Zaric, B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 138 : S5 - S5
  • [7] A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression
    Andric, Z.
    Ceric, T.
    Rancic, M.
    Jakopovic, M.
    Aix, S. Ponce
    Ramlau, R.
    Ulanska, M.
    Caldwell, C.
    Ferrari, D.
    Annis, A.
    Vukovic, V.
    Zaric, B.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1166 - S1166
  • [8] Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia
    Carvajal, Luis A.
    Ben-Neriah, Daniela
    Senecal, Adrien
    Bernard, Lumie
    Narayanagari, Swathi-Rao
    Kenworthy, Charles
    Thiruthuvanathan, Victor
    Guerlavais, Vincent
    Annis, D. Allen
    Bartholdy, Boris
    Will, Britta
    Anampa, Jesus
    Mantzaris, Ioannis
    Aivado, Manuel A.
    Singer, Robert H.
    Coleman, Robert
    Verma, Amit
    Steidl, Ulrich G.
    [J]. BLOOD, 2017, 130
  • [9] The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer models
    Pairawan, S. S.
    Yuca, E.
    Evans, K.
    Annis, A.
    Narasimhan, N.
    Sutton, D.
    Carvajal, L. A.
    Ren, J-G
    Santiago, S.
    Guerlavais, V.
    Akcakanat, A.
    Tapia, C.
    Dumbrava, E. E. Illeana
    Aivado, M.
    Meric-Bernstam, F.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [10] A phase I pharmacology study of the dual MDMX/MDM2 inhibitor, ALRN 6924, in healthy volunteers
    Voors-Pette, C.
    Aalders, W.
    Brill, M.
    Ferrari, D.
    Annis, A.
    Steidl, U.
    Aivado, M.
    Vukovic, V.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1222 - S1223
123